Company Encyclopedia
View More
name
Dynavax Tech
DVAX.US
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors.
1.945 T
DVAX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking100/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-7.14%D
    • Profit Margin-13.13%D
    • Gross Margin65.35%A
  • Growth ScoreC
    • Revenue YoY26.73%A
    • Net Profit YoY-311.94%E
    • Total Assets YoY-10.87%E
    • Net Assets YoY-21.61%E
  • Cash ScoreC
    • Cash Flow Margin-761.54%E
    • OCF YoY26.73%A
  • Operating ScoreD
    • Turnover0.33D
  • Debt ScoreC
    • Gearing Ratio43.57%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Entropy Technologies LP Has $190,000 Holdings in Dynavax Technologies Corporation $DVAX

    Entropy Technologies LP reduced its stake in Dynavax Technologies by 81.3% in Q2, now holding $190,000 worth of shares. Other institutional investors have also adjusted their positions. Analysts have mixed ratings on Dynavax, with a consensus 'Hold' rating and a price target of $24.33. The stock is trading at $11.43, with a market cap of $1.34 billion. Dynavax reported Q3 earnings of $0.21 per share, beating estimates. The company focuses on vaccines, including HEPLISAV-B for hepatitis B.

    Market Beat·
    US
    DVAX
    +0.09%
    Market Beat·
    US
    DVAX
    +0.09%

    Dynavax Technologies to Join Evercore Healthcare Conference

    Dynavax Technologies Corporation will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The presentation will be webcast and accessible through the Investors section of the company’s website. This event is part of Dynavax's engagement with the healthcare investment community.

    Reuters·
    US
    DVAX
    +0.09%
    Reuters·
    US
    DVAX
    +0.09%

    William Blair Issues Optimistic Forecast for DVAX Earnings

    William Blair analysts have raised their Q1 2026 earnings per share (EPS) estimate for Dynavax Technologies (NASDAQ:DVAX) from $0.11 to $0.14. The consensus estimate for the full year is $0.32 EPS. The company reported $0.21 EPS for the last quarter, exceeding expectations. Despite a recent stock decline of 4%, Dynavax has a market cap of $1.24 billion and a PE ratio of -22.93. Institutional investors hold 96.96% of the stock, indicating strong institutional interest.

    Market Beat·
    US
    DVAX
    +0.09%
    Market Beat·
    US
    DVAX
    +0.09%

    Dynavax Technologies (NASDAQ:DVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

    Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.21 EPS, exceeding expectations by $0.07. The company generated revenue of $94.88 million, surpassing the consensus estimate of $94.00 million. Despite a negative net margin of 16.67%, it achieved a positive return on equity of 5.10%. The stock traded at $10.30, with a market cap of $1.21 billion. Analysts have mixed ratings, with three recommending a buy and two a sell, while the average target price is $24.33.

    Market Beat·
    US
    DVAX
    +0.09%
    Market Beat·
    US
    DVAX
    +0.09%

    Dynavax Technologies Reports Strong Q3 Earnings and Strategic Growth

    Dynavax Technologies reported strong Q3 earnings, highlighting robust revenue growth and strategic advancements, particularly with its hepatitis B vaccine, HEPLISAV-B, which generated $90 million in net revenue. The company initiated Part 2 of its shingles vaccine study and executed a strategic deal with Vaxart for a COVID-19 oral vaccine. Dynavax authorized a $100 million share repurchase plan and reported a GAAP net income of $27 million. Despite concerns over seasonal impacts and a decrease in cash reserves to $648 million, the outlook remains positive with a goal of 60% market share in the U.S. adult hepatitis B vaccine market by 2030.

    Tip Ranks·
    US
    DVAX
    +0.09%
    Tip Ranks·
    US
    DVAX
    +0.09%
    © 2025 Longbridge｜Disclaimer